Helus Pharma
Canadian pharmaceutical company
From Wikipedia, the free encyclopedia
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.[1][2][3]
 | |
| Industry | Pharmaceutical; Psychedelic medicine |
|---|---|
| Founded | 2019 |
| Headquarters | , |
| Website | www |
The company's drug candidates include psilocybin (HLP001; CYB001),[4] HLP002 (CYB002; discontinued),[5] HLP003 (CYB003; deuterated psilocin),[6][7][8][9] HLP004 (CYB004; deuterated dimethyltryptamine (DMT)),[10] HLP005 (CYB005; deuterated phenethylamine derivative),[11][12][13] and HLP006 (CYB006).[14][15] Another drug that the company has developed is CYB210010 (2C-T-TFM).[16][17][18]
As of January 2025, HLP003 is in phase 3 clinical trials.[6][7] The drug is one of the only other psychedelics besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development.[19][20]
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics.[21] Helus Pharma was originally known as Cybin but changed its name in December 2025.[22]
